Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tvm Capital Life Science
BioCentury | Jul 22, 2023
Deals
July 21 Quick Takes: Gilead drops CD47 lead indication due to futility
Plus: Turnstone shares sag after upsized IPO, Idorsia unveils cost-cutting plan, and updates from ADC, the FTC, TVM, Verrica and more
BioCentury | Feb 9, 2023
Product Development
Feb. 8 Quick Takes: Galapagos slides on Phase III miss for filgotinib in Crohn’s
Plus: CureVac prices upsized $250M follow-on and updates from Novartis, UCB, TVM Capital and more
BioCentury | Feb 2, 2023
Regulation
Feb. 1 Quick Takes: FDA approves GSK’s daprodustat
Plus: Patient Square caps first fund at $3.9B, and updates from Verily-Otsuka Novartis, Evelo, Sherlock-Sense, Recurv and more
BioCentury | May 31, 2018
Product R&D
Lilly’s new leaf
How Lilly’s new R&D head aims to beef up the pharma’s first-in-class cache
BioCentury | May 18, 2018
Company News
Lilly continues to build cancer pipeline with AurKa acquisition
BioCentury | May 14, 2018
Company News
Lilly continues to build cancer pipeline with AurKa acquisition
Items per page:
1 - 10 of 19